

Coronary Stent Innovation: EPC Capture

Stephen Rowland Vice-President, Research & Development OrbusNeich Medical, Inc.

HBD East 2017 Think Tank Meeting At National Institute of Global Health and Medicine Tokyo, Japan: December 7, 2017




Disclosure Statement of Financial Interest

I, Stephen Rowland, am an employee of OrbusNeich Medical, Inc.



The COMBO Plus Dual Therapy Stent: Abluminal Bioresorbable Drug Delivery with Luminal EPC Capture



Stent & Delivery System

Highly conformable stent with excellent radial strength


Sirolimus & Polymer Matrix

Abluminal drug and bioabsorbable polymer matrix for control proliferation

CD34 Antibodies

Enable active capture of EPC for fast endothelial coverage

CD34 antibodies capture circulating EPCs which mature into functional endothelium



Following implantation, the immobilized CD34 antibodies are exposed to the circulating blood Circulating endothelial progenitor cells (EPC) are captures by antibody EPCs attach and differentiate into mature endothelial cells; an important step in reestablishing healthy neointima

HARMONEE

- HBD WG1 Global Clinical Trial
 - Adopted as Proof-of-Concept Project
- Single Protocol and Data Management
- Parallel trial approval process by PMDA & FDA
- Regulatory Objectives

larmonization By Doing

- Japan Shonin (market approval)
- Satisfy US feasibility & invasive follow up requirements

HBD I

Elumonization By Doing

Simultaneous Japan and US trial approval

• Parallel consultation pathways

fermonization By Doing

- Differing consultation processes
 - PMDA formal presentation, informal consultations on areas of concern, formal submission
 - FDA informal consultation, formal submission, formal consultations
- Global harmonization initiative IMDRF
 - HBD experience invaluable preparation





Challenges in Trial Design


- Device Effectiveness
 - Clinical
 - Angiographic
 - Mechanistic
- Device Safety
 - Clinical
 - HAMA
- Differences in clinical practice





HARMONEE Study

Enrollment Cohort Flow Diagram



*Includes an assumed 5% 1 yr lost to F/U

HBD Flamonization By Doing

AHJ 187 112-121 2017; Kong et al.

HARMONEE Status

- Protocol CTN approval by PMDA
- IDE approval by FDA

armonization By Doing

- 33 Japan sites and 17 US sites
- Enrollment completed June 2016
 - Japan enrollment 439 subjects
 - US enrollment 133 subjects
- 12-month follow-up period
 - Completed July 2017
- Primary study results presented as a First Report in the Main Arena at TCT 2017

furmonization By Doing

Harmonized Assessment by Randomized Multicenter Study of OrbusNEich's COMBO StEnt


The HARMONEE Primary Study Report

Mitchell W. Krucoff MD, FACC, FAHA, FSCAI* Professor of Medicine / Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical Research Institute *on behalf of the Japan-USA HARMONEE investigators






Enrollment & Follow-Up: ITT population





HARMONEE


Enrollment & Follow-Up: ITT population





HARMONEE

Enrollment & Follow-Up: ITT population



From Thought Leadership to Clinical Practice

HARMONEE 12-mo Trial Results

- Efficacy
 - Met non-inferiority in 12-month Target Vessel Failure [TVF] with 7.0% rate in Combo versus 4.2% rate in EES (Non-inferiority margin 7%, non-inferiority p-value 0.020)
 - Combo 12-month late loss and binary restenosis were comparable to EES
 - Met superiority in 12-month healthy strut coverage by OCT with 91.6% in Combo versus 74.8% in EES (p-value <0.001)
- Safety
 - No HAMA conversion and no Stent Thrombosis in Combo
 - No unanticipated device-related adverse events
- Manuscript in preparation

Next Steps

HARMOMEE Trial

- "Deep Dives" into sub-set and imaging data sets
- Long-term follow-up out to 5 years

Japan

larmonization By Doing

- Shonin Application
- PMS proposal

US

- Consultation on further trial requirements

HBD

15

Benefits of Participation in HBD

Overcoming Real Challenges


furmonization By Doins

- Internal organization Alignment
- •Clinical and regulatory objectives Japan "First" Approach
- •Trial approval in Japan and US Simultaneous
- •Site contracting & management Best Practices
- Regional clinical practice Protocol and Practice Guidelines
- •Safety reporting requirements Common Procedures

16

HARMONEE

Harmonized Assessment by Randomized, Multi-center Study Of the NovEl COMBO StEnt



HARMONEE Trial Organization

Study PIs	Shigeru Saito, Mitchell Krucoff
Study Chair	David F. Kong
Regional PIs	Shigeru Nakamura (Japan), Roxanna Mehran (USA)
Biostatistics	Hussein R. Al-Khalidi, Gudaye Tassisa
OCT Core	CRF: Akiko Maehara (Director)
FFR Core	CWR: Hiram Bezera (Director)
QCA Core	CRF: Philippe Généreux (Director)
DSMC	David Faxon (Chair), Alexandra Lansky, John Alexander, Taka Uchida, Jan Tijssen
CEC	Raj Mehta (Chair), Schuyler Jones (CEC-PI)
ARO	DCRI
SMO	DCRI, CMIC
Sponsor	OrbusNeich Medical, Ft Lauderdale and OMKK, Tokyo





Thank You

HBD East 2017 Think Tank Meeting At National Institute of Global Health and Medicine Tokyo, Japan: December 7, 2017